{
  "drug_name": "Cloxacillin",
  "tradename": "Cloxapen, Tegopen",
  "usage_and_dosing": {
    "general": [
      "Cloxacillin is an oral anti-staphylococcal semi-synthetic penicillin resistant to penicillinase. Active versus MSSA but not MRSA.",
      "Similar to Dicloxacillin, but Dicloxacillin blood levels are substantively higher. Hence, Dicloxacillin is the preferred oral anti-MSSA antibiotic.",
      "Oral Cloxacillin is no longer available in the U.S.",
      "Parenteral Cloxacillin was not approved in the U.S., but has been used elsewhere.",
      "Use in CNS infection: See comments."
    ],
    "adult_dose": {
      "oral": "250-500 mg po q6h",
      "iv": {
          "usual": "1-2 gm IV q6h",
          "severe_infection": "2 gm IV q4h"
      }
    },
    "pediatric_dose": {
      "dose_age_gt_28_days": "50-200 mg/kg/day (divided q6h)",
      "max_day": "-"
    }
  },
  "renal_adjustment": {
    "half_life_normal": "0.4",
    "half_life_esrd": "0.7",
    "dose_renal_function_normal": "250-500 mg po q6h",
    "crcl_or_egfr": "No dosage adjustment for renal impairment",
    "hemodialysis": "No data",
    "capd": "No data",
    "crrt": "No data",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No data",
    "moderate_impairment_child_pugh_b": "No data",
    "severe_impairment_child_pugh_c": "No data"
  },
  "adverse_effects": [
    "GI upset",
    "Rash, hypersensitivity reaction",
    "Hepatitis, interstitial nephritis, neutropenia"
  ],
  "pregnancy_risk": {
    "fda_risk_category": "No evidence of toxicity in humans or animals",
    "lactation": "Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {
    "preferred": [
        "Staphylococcus aureus, methicillin-sensitive (MSSA)",
        "Staphylococcus epidermidis, methicillin-susceptible (MSSE)",
        "Staphylococcus lugdunensis",
        "Staphylococcus sp., coagulase-negative (Methicillin susceptible); S. hominis, S. capitis, others"
    ],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "T>MIC",
    "preparations": "Cap (250, 500 mg), Injection",
    "food_recommendation": "Cap no food",
    "oral_absorption_percent": "50",
    "tmax_hr": "1-1.5",
    "peak_serum_conc_ug_ml": "7.5-14 (500 mg po, SD)",
    "peak_urine_conc_ug_ml": "No data",
    "protein_binding_percent": "95",
    "volume_of_distribution_vd_l_kg": "0.1 L/kg",
    "avg_serum_half_life_hr": "0.5",
    "elimination": "Renal, other",
    "bile_penetration_percent": "No data",
    "csf_blood_percent": "1.8 (CMI 2020;26:1415.e1)",
    "therapeutic_levels_in_csf": "Possibly",
    "auc_ug_hr_ml": "No data"
  },
  "major_drug_interactions": [
      {
          "drug": "Probenecid",
          "effect": "â†‘ cloxacillin",
          "management": "Monitor, adjust dosage"
      }
  ],
  "comments": [
      "Oral Cloxacillin has been used in treatment of Staph. aureus skin and skin structure infections.",
      "Use of oral Cloxacillin for completion of osteomyelitis therapy after initial intravenous treatment has been described (J Infect Dis 155:968, 1987).",
      "Use in staphylococcal CNS infection: Very limited historical data suggest cloxacillin can achieve bactericidal titers in the CSF when used in large doses of 12-18 grams/day (J Antimicrob Chemother 1983;12:607)."
  ]
}
